Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Conditions
Interventions
Single-Dose IV Oritavancin Diphosphate
IV Vancomycin
+1 more
Locations
1
United States
Sharp Chula Vista Medical Center
Chula Vista, California, United States
Start Date
December 1, 2010
Primary Completion Date
October 1, 2012
Completion Date
November 30, 2012
Last Updated
August 1, 2022
NCT06200207
NCT07379684
NCT07326670
NCT06649097
NCT06829238
NCT06594276
Lead Sponsor
Melinta Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions